

**Bexel Pharmaceuticals, Inc.**  
**Balance Sheet at at March 31, 2025 (Provisional)**

		March 31, 2025
<b>ASSETS</b>		
Current Assets		
Checking/Savings		
1010 · WFB #0131 - New Checking		5.00
1000 · WFB #4602 - Old Checking		0.00
Total Checking/Savings		5.00
Other Current Assets		
1620 · Receivable - Orchid		0.00
Total Other Current Assets		0.00
Total Current Assets		5.00
Fixed Assets		
1100 · Laboratory Equipment		
1101 · Laboratory Equip-Accum Depreciation	-8,886.78	
1102 · Laboratory Equipment Cost	8,886.78	
Total 1100 · Laboratory Equipment		0.00
1200 · Computers and Office Equip		
1201 · Computers-Accum Depreciation	-20,976.08	
1202 · Computers Cost	20,976.08	
Total 1200 · Computers and Office Equip		0.00
Total Fixed Assets		0.00
<b>TOTAL ASSETS</b>		<b>5.00</b>
<b>LIABILITIES &amp; EQUITY</b>		
Liabilities		
Current Liabilities		
Other Current Liabilities		
2100 · Payroll Liabilities	1,27,169.05	
2170 · Retirement Fidelity FPRS	2.20	
Total Other Current Liabilities	1,27,171.25	
Total Current Liabilities	1,27,171.25	
Long Term Liabilities		
2135 · Due to OrchidPharma, Inc.	49,989.00	
2130 · Intercompany - Orchid	54,71,500.00	
Total Long Term Liabilities	55,21,489.00	
Total Liabilities	56,48,660.25	
Equity		
3100 · Common Stock	21,002.02	
3150 · Preferred Stock	10,000.00	
3160 · Series D Preferred	4,090.25	
3200 · Additional Paid in Capital	1,83,38,881.27	
3400 · Treasury Stock	-13,00,460.94	
3900 · Retained Earnings	-2,27,22,970.85	
Total Equity	-56,48,655.25	
<b>TOTAL LIABILITIES &amp; EQUITY</b>		<b>5.00</b>

**BEXEL Pharmaceuticals, Inc.**  
**Profit & Loss**

April 2024 through March 2025

		Accrual Basis
		Apr' 24 - March' 25
Net Income		0.00
<u>Expenses</u>		
Bank Charges		0.00
IRS Charges		0.00
		0.00
Net Loss for the period		0.00

Provisional FS  
 S.K. Sahay